Effect of mammography on older women’s life expectancy still unclear.
It is still unknown if regular screening mammography would benefit women aged 65 and older, according to a study published in the Journal of General Internal Medicine.
Researchers from the University of California, San Francisco; the San Francisco VA Medical Center; and the University of California, Berkeley, conducted a systematic review to assess the quality and limitations of published studies examining benefits and harms of screening mammography in relation to comorbidity and age.
The researchers reviewed studies published between January 1980 and June 2013 that examined the benefits or harms of screening mammography among older women, in relation to comorbidity. Using data regarding setting, design, quality, screening schedule, measure of comorbidity, and estimates of benefits and/or harms, they identified seven articles out of 1,760 titles that met their criteria:[[{"type":"media","view_mode":"media_crop","fid":"46123","attributes":{"alt":"mammography","class":"media-image media-image-right","id":"media_crop_5346761876178","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"5332","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 120px; width: 180px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©zlikovec/Shutterstock.com","typeof":"foaf:Image"}}]]
• Two prospective cohort studies
• Two retrospective cohort studies
• Three decision analyses studies
The researchers did not identify any suitable randomized controlled trials.
The results found that four studies examined at least one measure of life expectancy or reduction in the risk of breast cancer death as a marker of benefit and three studies addressed the harms of screening mammography, including false-positive results. “Both cohort studies and decision analyses showed that screening benefits decreased with increasing age and comorbidity burden,” the authors wrote.
There is still limited evidence that suggest that women over the age of 65 without severe comorbidity would see any improvements to life expectancy as a result of routine mammography screening. “Given the potential for harm, it is unclear whether the magnitude of the benefit is sufficient to warrant regular screening,” the authors concluded. “Women, clinicians and policymakers should consider these factors in deciding whether continue screening.”
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.